Abstract Background Immune checkpoint inhibitor-based combinations represent the standard of care for advanced renal cell carcinoma (RCC). The OMNIVORE trial (NCT03652142) investigated a response-adaptive strategy including treatment discontinuation in early nivolumab responders (Arm A) and salvage ipilimumab addition...
M. Serzan, Wan-Ling Xie, B. McGregor et al.· The Oncologist· 0 citations
A scRNA-seq atlas of tumors from metastatic RCC found a novel factor, Hsp70, that in lymphocytes strongly predicts response and greatly extended PFS after ICI, indicating that Hsp70 expression in lymphocytes predicts response to ICI across timepoints and cohorts.
Ethan C. Burns, S. Kashima, Rishabh Rout et al.· The Oncologist· 0 citations
Abstract Background Select patients with locally advanced or metastatic renal cell carcinoma (RCC) are candidates for consolidative nephrectomy (CN) following immune checkpoint blockade (ICB). Existing cohorts have been limited by heterogeneous pathological assessment and small sample sizes, limiting validation of path...
Paulo Siqueira Do Amaral, R. Mehra, J. Gordetsky et al.· The Oncologist· 0 citations
Abstract Background Oligometastatic clear-cell renal cell carcinoma (ccRCC) is a biologically distinct, often indolent state where metastasis-directed therapy, including metastasectomy or SBRT, provides durable local control and delays systemic therapy. Randomized prospective trial evidence demonstrates a survival bene...
Abhirami Das, S. Balkhi, A. Mitta et al.· The Oncologist· 0 citations
Abstract Background Hypoxia signaling is a key driver of renal cell carcinoma (RCC) and is mediated by HIF-dependent transcription. ARNT (HIF-1β) is an essential HIF binding partner, but its expression and clinical relevance in RCC are poorly defined. With ARNT inhibitors in development, characterizing ARNT expression...
Yu-Wei Chen, S. Nazari, A. Elliott et al.· The Oncologist· 0 citations
A tissue residency gene program in Tex cells associated with non-response to immunotherapy was identified and nominates resident memory exhausted CD8+ T cells as a targetable subset of cells to improve CD8+ T cell-mediated anti-tumor immunity.
Rishabh Rout, S. Kashima, M. Hugaboom et al.· The Oncologist· 0 citations
It is found that baseline tumor infiltration by exhausted T cells with a resident memory phenotype (Tex-rm) is significantly associated with worse PFS in advanced RCC patients receiving ICI monotherapy or ICI+TKI combination therapy.
Zhao-Chen Ye, S. Kashima, Rishabh Rout et al.· The Oncologist· 0 citations
The vision is to establish JAK inhibition as a tractable strategy for restoring checkpoint sensitivity across solid tumors, providing the foundation for a biomarker-driven randomized phase 2 trial in checkpoint-refractory disease.
Rana Mckay, L.-J. Wei, Yu-Wei Chen et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
